At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed NSCLC, Stage IV with distant metastases, Stage IIIB with malignant pleural effusion, or recurrent disease
- ✓Measurable disease: ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓No more than 1 prior cytotoxic chemotherapy regimen for Stage IIIB/IV or recurrent disease
- ✓Life expectancy >3 months
- ✕Chemotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry
- ✕Radiotherapy within 3 weeks prior to study entry
- ✕Any other active malignancy in the past 5 years except non-melanoma skin cancers
- ✕Uncontrolled intercurrent illness including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness limiting compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating vorinostat and laboratory biomarker analysis for Recurrent Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 16 participants across 5 sites.
Detailed Summary
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Interventions
Given PO
Correlative studies